Advanced searches left 3/3

Colorectal Cancer - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 19 August 2022

* If you want to update the article please login/register

Epidemiological and Molecular Colorectal Cancer Registry

This is a registry that welcomes patients undergoing colorectal surgery for colorectal cancer. The Registry holds tumor tissue and blood samples banks used to analyze different genetic variants and disease-specific biomarkers in patients with Lynch syndrome and others hereditary cancers. The aim of this registry is to establish the appropriate funding to support basic and clinical research on colorectal cancer research within the Hospital Italiano de Buenos Aires and promote scientific collaborations between the HIBA and other organizations within and outside the region. Objective 2: Goal 2: The CRC's connectivity and expansion of the bank of biological samples and tumor samples can be enhanced by logistics. Objective 3: Objective 3: Objective 3: The development of computer software to store patient data in a flexible manner.

Source link: https://clinicaltrials.gov/ct2/show/NCT02781337


Colorectal Cancer Screening Cohort Study in Shougang Community Population Based on Polygene Methylation Detection Technology

The participants were found to have colorectal cancer by examination, and the patients who were treated after polyps or adenomas were also identified during colonoscopy, which reached the study endpoint, according to the study's conclusion.

Source link: https://clinicaltrials.gov/ct2/show/NCT05485077


High Definition Single Cell Analysis in Colorectal Cancer

Using single-cell high-content analysis, including gene copy number variation and to find one or more biopsies from solid tumor touch preparations and patient population can determine the liquid and solid biopsy correlation for each patient and the patient population. Comparing two pre-resection liquid biopsy samples obtained a week before and on the day of surgery to determine the biological reliability and reproducibility of the bio-signatures. Compare biosignatures between resected metastatic liver tumor tissue, primary colon tumor tissue, and pre-operative blood samples. Compare biosignatures between blood samples before and during resection with those obtained after resection and at the time of recurrence. Patients are screened 1 week before and after surgery, before and after surgery on the same day, and 1 week and three months after surgery.

Source link: https://clinicaltrials.gov/ct2/show/NCT02809716


Informed Choice Intervention for Colorectal Cancer Screening: Compass

After the video, and after their index visit, subjects in all intervention arms would complete surveys on the intention to screen for CRC and preference for screening modality prior to viewing the article. Subjects will be surveyed and medical data collected every year for up to six years to determine adherence to CRC screening and CRC screening findings.

Source link: https://clinicaltrials.gov/ct2/show/NCT05246839


Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)

Patients with detectable cancer-specific plasma changes have a long life. Overall survival of patients with detectable cancer-specific plasma alterations appears to be high. Sensitivity, specificity, positive predictive, and negative predictive values of cancer-specific plasma alterations in detecting recurrences are all related. Correlation between cancer-specific changes in plasma and tissue, as well as those with findings including DFS and OS. OUTLINE: Patients obtain blood samples at baseline, during any neoadjuvant therapy course, prior to surgical resection, and up to 4 times per year for up to 5 years. At the time of surgical transplantation, patients also collect tissue samples at the time of surgical resection. Patients' medical information can also be reviewed.

Source link: https://clinicaltrials.gov/ct2/show/NCT04739072


Non-invasive Identification of Colorectal Cancer and Adenomas in Early Stages

The aim of this prospective multi-center observational research is to develop and evaluate a blood-based glycoproteomic test for the early detection of advanced adenoma and colorectal cancer by collecting blood samples and related clinical data from participants undergoing colonoscopy routinely, as well as participants undergoing colonoscopy for surveillance or diagnostic indications.

Source link: https://clinicaltrials.gov/ct2/show/NCT05445570


The Role of the Microbiome in Colorectal Cancer Onset and Progression

Those that are polyp/cancer free, pre-cancerous, and confirmed primary diagnosis of colorectal cancer will be recruited. Participants are also encouraged to submit tissue or tumor samples if requested by their healthcare provider during a national health biopsy procedure. The clinical staff at each study site will gather biopsy samples for this test. Timepoint 1, Timepoint 2, Timepoint 3, Timepoint 4, and Timepoint 5 are among the five timepoints in this analysis. TP1 is the first diagnosis of cancer, in which the stage of cancer is determined by imaging or colonoscopy findings reveals the stage of disease. Samples for cancer patients will be collected 45 +/- 15 days after all treatments have been completed. They were diagnosed as cancer-free and precancerous individuals and 1,2, and 5 years respectively, in 1, 2 and 3 years respectively, and 1, 2 and 3 years respectively, before standard of care therapy for the cancer patients.

Source link: https://clinicaltrials.gov/ct2/show/NCT05368688


Time Longitudinal Study of the Microbiome in Colorectal Cancer Subjects

The aim of this research was to find out how colon cancer causes colon cancer and how it can shift due to colon cancer. Participation in the study requires stool samples before and after your surgery, as well as samples of residual colon tissue from your surgery.

Source link: https://clinicaltrials.gov/ct2/show/NCT03951792


A Community-Based Educational Intervention to Improve Colorectal Cancer Screening

In the Sidney Kimmel Cancer Center catchment area, Develop a culturally tailored colorectal cancer education program for underserved and underrepresented populations with a focus on African American, Latinx, and Asian. Participants in an interview of over 60 minutes exploring facilitators and barriers to colorectal cancer screening, which are important academic determinants to include in the educational process, as well as insights into the best use of the National Cancer Institute's Screen to Save materials.

Source link: https://clinicaltrials.gov/ct2/show/NCT04392050


Gut Microbiome and Oral Fluoropyrimidine Study in Patients With Colorectal Cancer

Patients treated with oral fluoropyrimidine CAP as part of a standard of care chemotherapy. Cohort A: patients treated with oral fluoropyrimidine CAP. Patients treated with TAS-102 included those receiving it in combination with Y-90 radioembolization as part of a clinical study. Patients with two analyzable stool samples, as well as a baseline sample and at least one on-treatment sample, are included in endpoint analysis.

Source link: https://clinicaltrials.gov/ct2/show/NCT04054908

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions